

Economic impact of a genetic test for cisplatin-induced ototoxicity

F Dionne, C Mitton, R Rassekh,
B Brooks, C Ross, M Hayden
and B Carleton

The Pharmacogenomics Journal (2012) **12**, 359; doi:10.1038/tpj.2011.21

Correction to: *The Pharmacogenomics Journal* (2012) **12**, 205–213; doi:10.1038/tpj.2011.15; published online 19 April 2011

The above article was published with incomplete affiliations. The authors apologize for this error. The authors, with the correct affiliations, are listed below.

F Dionne¹, C Mitton^{1,2}, R Rassekh³, B Brooks^{4,5}, C Ross^{6,7}, M Hayden^{6,7}
and B Carleton^{6,8,9}

¹Centre for Clinical Epidemiology and Evaluation, VCHRI, Vancouver, Canada; ²School of Population and Public Health, University of British Columbia, Vancouver, Canada; ³Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, British Columbia Children's Hospital, Vancouver, Canada; ⁴Audiology and Speech Pathology Department, British Columbia's Children's Hospital, Vancouver, Canada; ⁵School of Audiology and Speech Sciences, University of British Columbia, Vancouver, Canada; ⁶Child and Family Research Institute, Children's and Women's Health Research Centre of B.C., Vancouver, Canada; ⁷Department of Medical Genetics, University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada; ⁸Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada and ⁹Department of Paediatrics, Pharmaceutical Outcomes Programme, University of British Columbia, Vancouver, Canada